JP2009537608A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537608A5
JP2009537608A5 JP2009511524A JP2009511524A JP2009537608A5 JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5 JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009511524 A JP2009511524 A JP 2009511524A JP 2009537608 A5 JP2009537608 A5 JP 2009537608A5
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
heavy chain
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537608A (ja
JP5420399B2 (ja
Filing date
Publication date
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/055029 external-priority patent/WO2007137984A2/en
Publication of JP2009537608A publication Critical patent/JP2009537608A/ja
Publication of JP2009537608A5 publication Critical patent/JP2009537608A5/ja
Application granted granted Critical
Publication of JP5420399B2 publication Critical patent/JP5420399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511524A 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体 Active JP5420399B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0610438.4 2006-05-25
GB0611046.4 2006-06-05
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins
PCT/EP2007/055029 WO2007137984A2 (en) 2006-05-25 2007-05-23 Modified humanised anti-interleukin-18 antibodies

Publications (3)

Publication Number Publication Date
JP2009537608A JP2009537608A (ja) 2009-10-29
JP2009537608A5 true JP2009537608A5 (OSRAM) 2013-07-25
JP5420399B2 JP5420399B2 (ja) 2014-02-19

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511524A Active JP5420399B2 (ja) 2006-05-25 2007-05-23 改変型ヒト化抗インターロイキン−18抗体

Country Status (22)

Country Link
US (5) US8133978B2 (OSRAM)
EP (1) EP2027157B1 (OSRAM)
JP (1) JP5420399B2 (OSRAM)
KR (1) KR101416078B1 (OSRAM)
AR (1) AR061115A1 (OSRAM)
AU (1) AU2007267213B2 (OSRAM)
BR (1) BRPI0711908B8 (OSRAM)
CA (1) CA2652733C (OSRAM)
CR (1) CR10468A (OSRAM)
EA (1) EA017303B1 (OSRAM)
ES (1) ES2514495T3 (OSRAM)
IL (1) IL194995A0 (OSRAM)
MA (1) MA30486B1 (OSRAM)
MX (1) MX2008014842A (OSRAM)
MY (1) MY157173A (OSRAM)
NO (1) NO341921B1 (OSRAM)
NZ (1) NZ572565A (OSRAM)
PE (1) PE20080262A1 (OSRAM)
SG (1) SG172625A1 (OSRAM)
TW (1) TWI422387B (OSRAM)
WO (1) WO2007137984A2 (OSRAM)
ZA (1) ZA200809662B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2734358A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
KR101252362B1 (ko) 2008-08-27 2013-04-08 에프. 호프만-라 로슈 아게 고친화성 항체를 스크리닝하는 방법
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd VARIANT OF A CONSTANT ANTIBODY REGION
EP2470563B1 (en) 2009-08-25 2016-04-13 F.Hoffmann-La Roche Ag Velocity factor
JP2013518863A (ja) * 2010-02-09 2013-05-23 グラクソ グループ リミテッド 代謝障害の治療
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 TNF-α 결합 단백질
LT2643352T (lt) * 2010-11-23 2018-08-10 Glaxo Group Limited Antigeną onkostatiną m (osm) surišantys baltymai
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP2924117B1 (en) 2012-11-21 2019-08-14 KM Biologics Co., Ltd. Novel human antibody against il-18
ES2869396T3 (es) * 2013-05-15 2021-10-25 Medimmune Ltd Purificación de polipéptidos producidos de manera recombinante
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗il-6受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
WO2024261470A1 (en) 2023-06-20 2024-12-26 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis
WO2025229563A1 (en) * 2024-05-03 2025-11-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating inflammatory bowel disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP2952750B2 (ja) * 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
ES2361267T3 (es) * 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
BR0108188A (pt) 2000-02-10 2003-02-25 Abbott Lab Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
DE60144514D1 (de) 2000-02-21 2011-06-09 Merck Serono Sa Verwendung von il-18 inhibitoren
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
AU2002224417A1 (en) 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20050074434A1 (en) 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン-18抗体およびその断片、並びにそれらの利用方法
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2562953A1 (en) * 2004-03-30 2005-10-13 Glaxo Group Limited Humanized and chimeric anti-osm antibodies
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
CA2635445A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
CA2734358A1 (en) 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Similar Documents

Publication Publication Date Title
JP2009537608A5 (OSRAM)
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
CN108367075B (zh) 4-1bb结合蛋白及其用途
JP2022061992A5 (OSRAM)
Almagro et al. Humanization of antibodies
JP2015504306A5 (OSRAM)
CN104774266B (zh) 白介素-13结合蛋白
JP2014534242A5 (OSRAM)
RU2009124591A (ru) Соединения
US20100261620A1 (en) Methods of Humanizing and Affinity-Maturing Antibodies
JP2020519308A5 (OSRAM)
JP2010524435A5 (OSRAM)
JP2020517249A5 (OSRAM)
RU2004135103A (ru) Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике
RU2009128064A (ru) Антитела к cd44
AU2013291937A1 (en) Antibodies to highly conserved targets
RU2008137763A (ru) Связующий элемент для рецептора gm-csf
TW201014602A (en) Prostaglandin E2 binding proteins and uses thereof
CN110612308A (zh) 制备pH依赖性抗体的方法
SG184473A1 (en) Tnf-alpha binding proteins
JP2010535012A5 (OSRAM)
RU2013110874A (ru) Антитела против il-18r1 и их применения
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2013509158A5 (OSRAM)